Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875702 · ClinicalTrials.gov registry record · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
A Phase 4 study of Gout, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 650
- Enrollment target
- 7
- Study locations
NCT04875702: Recruiting Phase 4 study of Gout, sponsored by Massachusetts General Hospital.
NCT04875702 is a Phase 4 study of Gout that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 650 participants, below the 8,869-participant average among 34 other Gout trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04875702, a Phase 4 study of Gout, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 650 participants
- Enrollment target
- 7
- Study locations
Study Summary
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Primary Outcome
number of gout flares occurring during two years of follow-up between the TTT-SU and TTASx groups
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Naproxen 250 MG
- DRUG Colchicine 0.6 mg
- DRUG Colchicine 1.2 mg
- DRUG Naproxen 500 Mg
Study Locations (7)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital (BWH) - Boston
- Boston Medical Center (BMC) - Boston
Alabama
- The University of Alabama at Birmingham - South Birmingham
California
- UCLA Health - Santa Monica
New York
- NYU Langone - New York
West Virginia
- West Virginia University (Including Mobile Clinical Trials Unit) - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 4 |
What NCT04875702 shows while recruiting
NCT04875702 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 8,869-participant average among 34 other Gout trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 5 interventions - of which Allopurinol is the first listed.
NCT04875702 lists 7 locations in 5 states (Massachusetts, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT04875702 about?
NCT04875702 is a clinical study titled "Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout". The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpo...
What is the current status of trial NCT04875702?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 650 participants. The study started on 2024-02-22. Estimated completion is 2028-10-31.
What conditions does trial NCT04875702 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT04875702?
The interventions under investigation include: Allopurinol (DRUG), Naproxen 250 MG (DRUG), Colchicine 0.6 mg (DRUG), Colchicine 1.2 mg (DRUG), Naproxen 500 Mg (DRUG).
Who is sponsoring clinical trial NCT04875702?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04875702 being conducted?
This trial has 7 study locations across Alabama, California, Massachusetts, New York, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04875702's enrollment target sits among peer trials
650 5th of 34 higher than 30 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
RECRUITING · Phase 4
-
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
ACTIVE NOT RECRUITING · Phase 4
-
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
COMPLETED · Phase 4
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
- NCT05253235 · 650 participants · NA
Health and Resilience Projects: Foundations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI